Valuation: Epigenomics AG

Market Cap 763K 850K 704K 639K 1.19M 80.75M 1.21M 8.45M 3.35M 42.32M 3.19M 3.12M 134M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.73M 13.07M 10.83M 9.82M 18.36M 1.24B 18.58M 130M 51.57M 651M 49.06M 48.01M 2.06B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
76.6%
Yield 2024 *
-
Yield 2025 -
Current month-8.42%
1 month-8.42%
3 months-7.45%
6 months-6.45%
Current year-3.33%
1 week 0.87
Extreme 0.87
0.88
1 month 0.87
Extreme 0.87
1.19
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3
5 years 0.5
Extreme 0.5
20
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/12/22 Buy

Chief Financial Officer

2,000 0.0122%
07/09/21 Sell

Director

7,790 0.0637%
01/02/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-2.25%-68.36% 853K
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+7.26%+11.51%+77.95% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.58%+1.78%+41.55%+133.98% 38.33B
Weighted average by Cap. -0.73%+1.72%+43.49%+155.36%

Financials

2024 2025
Net sales - 24K 26.74K 22.16K 20.1K 37.56K 2.54M 38.02K 266K 106K 1.33M 100K 98.23K 4.22M
Net income -3.35M -3.73M -3.1M -2.81M -5.25M -355M -5.31M -37.11M -14.74M -186M -14.02M -13.72M -590M -314K -350K -290K -263K -491K -33.23M -497K -3.48M -1.38M -17.42M -1.31M -1.29M -55.24M
Net Debt 10.46M 11.65M 9.65M 8.75M 16.36M 1.11B 16.56M 116M 45.97M 580M 43.73M 42.79M 1.84B 10.97M 12.22M 10.13M 9.18M 17.16M 1.16B 17.37M 121M 48.22M 608M 45.87M 44.89M 1.93B
Projected Income Statement - Annual - Epigenomics AG
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
2
Date Price Change Volume
27/10/26 €0.8700 0.00% 0
26/10/26 €0.8700 0.00% 80
23/10/26 €0.8700 -1.14% 30
22/10/26 €0.8800 +1.15% 60
21/10/26 €0.8700 0.00% 0

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Epigenomics AG